Loading organizations...
Loading organizations...
Biosplice Therapeutics develops first-in-class small-molecule therapies engineered to precisely modulate alternative pre-mRNA splicing. The company's core approach involves targeting the CLK/DYRK family kinases, which play a critical role in controlling proteome diversification. This foundational technology allows Biosplice to intervene at a fundamental biological level, creating therapeutic candidates designed to correct dysregulated splicing patterns implicated in various human diseases.
The company was founded in 2008 by Osman Kibar. His insight centered on the profound impact of alternative splicing dysregulation as a root cause of numerous debilitating conditions. This understanding propelled the development of a proprietary platform aimed at discovering and advancing novel small molecules that can therapeutically restore healthy splicing, thereby addressing underlying disease mechanisms rather than just symptoms.
Biosplice’s therapeutic candidates are intended for patients facing significant unmet medical needs in areas such as osteoarthritis, oncology, neurology, and diabetes. The company's vision is to advance these targeted therapies through clinical development and ultimately deliver them to patients, with the goal of restoring health and significantly improving patient outcomes across a spectrum of challenging diseases.
Biosplice Therapeutics has raised $558.0M across 2 funding rounds.
Biosplice Therapeutics has raised $558.0M in total across 2 funding rounds.
Biosplice Therapeutics develops first-in-class small-molecule therapies engineered to precisely modulate alternative pre-mRNA splicing. The company's core approach involves targeting the CLK/DYRK family kinases, which play a critical role in controlling proteome diversification. This foundational technology allows Biosplice to intervene at a fundamental biological level, creating therapeutic candidates designed to correct dysregulated splicing patterns implicated in various human diseases.
The company was founded in 2008 by Osman Kibar. His insight centered on the profound impact of alternative splicing dysregulation as a root cause of numerous debilitating conditions. This understanding propelled the development of a proprietary platform aimed at discovering and advancing novel small molecules that can therapeutically restore healthy splicing, thereby addressing underlying disease mechanisms rather than just symptoms.
Biosplice’s therapeutic candidates are intended for patients facing significant unmet medical needs in areas such as osteoarthritis, oncology, neurology, and diabetes. The company's vision is to advance these targeted therapies through clinical development and ultimately deliver them to patients, with the goal of restoring health and significantly improving patient outcomes across a spectrum of challenging diseases.
Biosplice Therapeutics has raised $558.0M in total across 2 funding rounds.
Biosplice Therapeutics's investors include Joy Ghosh, Sands Capital, SymBiosis II, Verition Fund Management.
Biosplice Therapeutics has raised $558.0M across 2 funding rounds. Most recently, it raised $120.0M Other Equity in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 15, 2021 | $120.0M Other Equity | Joy Ghosh, Sands Capital, SymBiosis II, Verition Fund Management | |
| Aug 6, 2018 | $438.0M Series A |